Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Kiadis Pharma NV (KDS)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Kiadis Pharma historical data, for real-time data please try another search
5.460 0.000    0.00%
24/05 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Netherlands
ISIN:  NL0011323407 
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 5.370 - 5.460
Kiadis Pharma 5.460 0.000 0.00%

Kiadis Pharma NV Company Profile

 
Get an in-depth profile of Kiadis Pharma NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

103

Equity Type

ORD

Kiadis Pharma N.V., a biopharmaceutical company, develops NK-cell-based medicines for the treatment of life-threatening diseases in the Netherlands. Its lead product candidate is K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol, as well as for the treatment of liquid and solid tumors and infectious diseases; and K-NK003 that is in Phase II clinical study for the treatment of patients with acute myeloid leukemia relapse/refractory. The company is also developing K-NK-ID101, which is in Phase I/II a clinical trial for the treatment of COVID-19 infection; K-NK00X, which is in preclinical stage with K-NK-cell therapies for the treatment of hematologic and solid cancers; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for a range of other cancers and infectious diseases. It has a collaboration agreement with Sanofi. The company was founded in 1997 and is based in Amsterdam, Netherlands. Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.

Contact Information

Address Paasheuvelweg 25A
Amsterdam, 1105 BP
Netherlands
Phone 31 20 240 5250
Fax 31 20 240 5251
Web
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

KDS Comments

Write your thoughts about Kiadis Pharma NV
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
René van Dalen
René van Dalen Dec 16, 2020 6:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
wat een vreemde daling ineens vandaag ?
Reply
0 0
Report
gennadios surailidis
gennadios Sep 09, 2019 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
do you think Mr. Bert the price of Kiadis will rise up to 10 euros ? please ?
Reply
0 2
Report
Sep 04, 2019 5:24AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
KDS ‘til 40 ? Probably
Reply
0 1
Report
MfB Iod
MfB Iod Jul 01, 2019 4:53AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what happened?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email